Trial Profile
An EORTC-IDBBC/ECSG Phase II Study Evaluating The Role Of The Multi-Drug Resistance (MDR) Reversor, R101933, In Patients With Taxane Refractory Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2015
Price :
$35
*
At a glance
- Drugs R 101933 (Primary) ; Docetaxel; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 09 Sep 2005 New trial record.